- ISIN
- US03969K1088
- CUSIP
- 03969K108
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jan 31, 2020
Highlights
- Market Cap
- $3.45B
- Enterprise Value
- $3.44B
- EPS (TTM)
- -$0.02
- Total Revenue (TTM)
- $415.62M
- Gross Profit (TTM)
- $377.98M
- EBITDA (TTM)
- $12.21M
- Year Range
- $13.06 - $31.77
- Target Price
- $35.50
- ROA (TTM)
- -0.52%
- ROE (TTM)
- -1.25%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ARQT Performance Chart
Arcutis Biotherapeutics, Inc. (ARQT) is down 8.2% since the beginning of the year. At $27 per share, ARQT is trading 16.1% below its 52-week high of $32. Investors who bought $1,000 worth of ARQT shares 5 years ago would now be looking at an investment worth $992.
Loading charts...
Returns By Period
Arcutis Biotherapeutics, Inc. (ARQT) has returned -8.20% so far this year and 92.91% over the past 12 months.
Arcutis Biotherapeutics, Inc.
- 1D
- 1.72%
- 1M
- 27.80%
- YTD
- -8.20%
- 6M
- -10.84%
- 1Y
- 92.91%
- 3Y*
- 44.81%
- 5Y*
- -0.16%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
ARQT Monthly Returns History
Based on dividend-adjusted daily data since Jan 31, 2020, ARQT's average daily return is +0.12%, while the average monthly return is +3.06%. At this rate, an investment would double in approximately 1.9 years.
Historically, 53% of months were positive and 47% were negative. The best month was Jan 2024 with a return of +81.7%, while the worst month was Oct 2023 at -57.6%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 4 months.
On a daily basis, ARQT closed higher 49% of trading days. The best single day was Mar 19, 2020 with a return of +36.4%, while the worst single day was May 10, 2023 at -18.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -12.64% | 6.31% | -12.64% | -1.44% | -7.58% | 24.23% | -8.20% | ||||||
| 2025 | -4.95% | 3.40% | 14.24% | -4.67% | -12.54% | 7.52% | 3.99% | 6.45% | 21.46% | 34.27% | 21.10% | -5.25% | 108.47% |
| 2024 | 81.73% | 75.13% | -3.60% | -16.04% | 0.48% | 11.24% | 8.28% | 8.04% | -14.52% | -10.65% | 56.92% | 6.83% | 331.27% |
| 2023 | 11.96% | -2.35% | -32.01% | 25.82% | -45.74% | 26.90% | 14.48% | -21.72% | -37.82% | -57.63% | -18.22% | 75.54% | -78.18% |
| 2022 | -27.15% | 17.80% | 8.20% | 4.83% | 3.42% | 2.06% | 13.84% | 11.09% | -29.09% | -7.48% | -2.55% | -14.10% | -28.64% |
| 2021 | -2.99% | 25.21% | -15.34% | 15.80% | -21.34% | 3.57% | -14.51% | -9.26% | 12.85% | -11.34% | -21.77% | 25.17% | -26.27% |
Benchmark Metrics
Arcutis Biotherapeutics, Inc. has an annualized alpha of 17.07%, beta of 1.03, and R2 of 0.08 versus S&P 500 Index. Calculated based on daily prices since January 31, 2020.
- This stock participated in 158.67% of S&P 500 Index downside but only 130.58% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.08 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 17.07%
- Beta
- 1.03
- R²
- 0.08
- Upside Capture
- 130.58%
- Downside Capture
- 158.67%
Return for Risk
Risk / Return Rank
ARQT ranks 81 for risk / return — in the top 81% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Arcutis Biotherapeutics, Inc. (ARQT) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ARQT | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.42 | ||
| Sortino ratioReturn per unit of downside risk | -0.35 | ||
| Omega ratioGain probability vs. loss probability | 1.30 | 1.37 | -0.07 |
| Calmar ratioReturn relative to maximum drawdown | 2.49 | 2.78 | -0.29 |
| Martin ratioReturn relative to average drawdown | 5.68 | 12.44 | -6.76 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Arcutis Biotherapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Arcutis Biotherapeutics, Inc. was 95.02%, occurring on Nov 30, 2023. The portfolio has not yet recovered.
The current Arcutis Biotherapeutics, Inc. drawdown is 27.91%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2023 bear market2023 | -95.02%Nov 2023 | 2y 9mo | — | 5y 4moFeb 2021 - now |
2020 bear market2020 | -51.71%Oct 2020 | 7mo 10d | 3mo 11d | 10mo 21dMar 2020 - Feb 2021 |
COVID crash2020 | -39.40%Mar 2020 | 7d | 2d | 9dMar 2020 - Mar 2020 |
COVID crash2020 | -6.89%Feb 2020 | 1d | 11d | 12dFeb 2020 - Mar 2020 |
2020 pullback2020 | -5.42%Jan 2020 | 0s | 3d | 3dJan 2020 - Feb 2020 |
Drawdown Indicators
| ARQT | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -95.02% | -56.78% | -38.24% |
Max Drawdown (1Y)Largest decline over 1 year | -37.50% | -9.10% | -28.40% |
Max Drawdown (3Y)Largest decline over 3 years | -83.24% | -18.90% | -64.34% |
Max Drawdown (5Y)Largest decline over 5 years | -93.28% | -25.43% | -67.85% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -27.91% | -1.80% | -26.11% |
Average DrawdownAverage peak-to-trough decline | -50.01% | -10.71% | -39.30% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 16.43% | 2.03% | +14.40% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Arcutis Biotherapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Arcutis Biotherapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ARQT relative to other companies in the Biotechnology industry. Currently, ARQT has a P/S ratio of 8.4. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ARQT in comparison with other companies in the Biotechnology industry. Currently, ARQT has a P/B value of 18.2. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ARQT
Add Arcutis Biotherapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ARQT